BIOVENTUS INC. - CLASS A COMMON STOCK

Bioventus to Report Third Quarter of Fiscal Year 2023 Financial Results on November 7, 2023

31 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Bioventus to Present at the Cantor Global Healthcare Conference

19 Sep 2023 21:52:45 By Nasdaq GlobeNewswire

Bioventus to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

06 Sep 2023 16:30:00 By Nasdaq GlobeNewswire

Bioventus Reports Second Quarter Financial Results; Introduces Full Year 2023 Financial Guidance

08 Aug 2023 07:30:01 By Nasdaq GlobeNewswire

Bioventus to Present at the Canaccord Genuity 43rd Annual Global Growth Conference

04 Aug 2023 08:30:00 By Nasdaq GlobeNewswire

Bioventus to Report Second Quarter of Fiscal Year 2023 Financial Results on August 8, 2023

01 Aug 2023 17:35:30 By Nasdaq GlobeNewswire

Bioventus Completes Divestiture of its Wound Business

23 May 2023 07:30:00 By Nasdaq GlobeNewswire

Bioventus Reports First Quarter Financial Results

16 May 2023 16:15:00 By Nasdaq GlobeNewswire

Bioventus Reschedules Reporting of First Quarter Fiscal Year 2023 Financial Results to After Market Close on May 16, 2023

15 May 2023 17:33:04 By Nasdaq GlobeNewswire

Bioventus Reschedules Earnings Call to May 16, 2023; Files for Extension to File Form 10-Q for the Period Ended April 1, 2023

11 May 2023 07:00:02 By Nasdaq GlobeNewswire

Bioventus Announces Divestiture of its Wound Business

10 May 2023 09:00:00 By Nasdaq GlobeNewswire

Bioventus to Report First Quarter of Fiscal Year 2023 Financial Results on May 11, 2023

03 May 2023 08:30:00 By Nasdaq GlobeNewswire

Bioventus Announces CEO Leadership Change

05 Apr 2023 08:00:00 By Nasdaq GlobeNewswire

Bioventus Reports Fourth Quarter and Full-Year 2022 Financial Results

31 Mar 2023 07:30:01 By Nasdaq GlobeNewswire

Bioventus Enters into an Amendment with its Credit Agreement Lenders to Enhance Financial and Operational Flexibility

31 Mar 2023 07:00:00 By Nasdaq GlobeNewswire

Bioventus Reschedules Reporting of Fourth Quarter Fiscal Year 2022 Financial Results to March 31, 2023

29 Mar 2023 08:55:09 By Nasdaq GlobeNewswire

Bioventus to Report Fourth Quarter of Fiscal Year 2022 Financial Results on March 30, 2023

16 Mar 2023 08:30:00 By Nasdaq GlobeNewswire

Bioventus Enters into Settlement Agreement to Preserve Maximum Optionality – Up To $350mm of Potential Liability Reduction and a Release of Future Claims related to the CartiHeal Acquisition

28 Feb 2023 07:30:00 By Nasdaq GlobeNewswire

Bioventus to Present at the 41st Annual J.P. Morgan Healthcare Conference

04 Jan 2023 07:00:00 By Nasdaq GlobeNewswire

Bioventus Issues Revised Third Quarter Results; Updates Full-Year 2022 Financial Guidance

21 Nov 2022 17:15:01 By Nasdaq GlobeNewswire